key: cord-0706933-lonc5cpy
authors: Tleyjeh, Imad M.; Kashour, Zakariya; Damlaj, Moussab; Riaz, Muhammad; Tlayjeh, Haytham; Altannir, Mustafa; Altannir, Youssef; Al-Tannir, Mohamad; Tleyjeh, Rana; Hassett, Leslie; Kashour, Tarek
title: Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis
date: 2020-11-05
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.10.036
sha: 6b7f1e8d3aa1c18ac7204f20edd22499030fbf97
doc_id: 706933
cord_uid: lonc5cpy

BACKGROUND: Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated with multi-organ damage and death in severe COVID-19 disease. OBJECTIVES: To perform a living systematic review of the literature about the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients. DATA SOURCES: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Web of Science, Scopus up, preprint servers and Google up to October 8, 2020. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials (RCTs) and observational studies at low or moderate risk of bias. PARTICIPANTS: Hospitalized COVID-19 patients. INTERVENTIONS: Tocilizumab vs. placebo or standard of care. METHODS: We pooled crude risk ratios (RRs) of RCTs and adjusted RRs from cohorts, separately. We evaluated between-studies inconsistency with I(2). We assessed the certainty of evidence using the GRADE approach. RESULTS: Of 1156 citations, 24 studies were eligible (5 RCTs and 19 cohorts). Five RCTs at low risk of bias, with 1325 patients examined the effect of tocilizumab on short term mortality; pooled RR was 1.09 (95% CI 0.80-1.49, I(2) = 0 %). Four RCTs with 771 patients examined the effect of tocilizumab on risk of mechanical ventilation; pooled RR was 0.71 (95% CI 0.52-0.96, I(2) = 0 %), with a corresponding number needed to treat 17 (95% CI 9-100). Among 18 cohorts at moderate risk of bias with 9850 patients, the pooled adjusted RR for mortality was 0.58 (95% CI 0.51-0.66, I(2)= 2.5%). This association was observed across all stages of COVID-19 severity. Data from the RCTs did not show higher risk of infections or adverse events with tocilizumab; pooled RR 0.63 (95% CI 0.38-1.06, 5 RCTs) and 0.83 (95% CI 0.55-1.24, 5 RCTs), respectively. CONCLUSION: Cumulative moderate certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. While RCTs showed that tocilizumab did not reduce short-term mortality, low certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. We did not observe a higher risk of infections or adverse events with tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 treatment.

Since its emergence in December 2019, SARS-CoV-2 virus has infected millions of people across the globe and claimed hundreds of thousands of human lives, and negatively impacted the economy of numerous countries. Although the majority of SAR-CoV-2 infected patients who developed COVID-19 disease manifest only mild symptoms, about 14% of patients develop severe symptoms and 5% develop critical disease defined by respiratory failure, shock and/or multiorgan failure. [1] The innate and adaptive immune responses react appropriately in the majority of infected people and lead to control of the infection with no significant damage to the host tissues. Macrophages get activated by damage-associated molecular patterns (DAMPs) from damaged cells like heatshock proteins and hyaluronan fragments, and liberated pathogen-associated molecular patterns (PAMPS), like viral RNA. These molecules activate toll-like receptors (TLRs) and NLRP3

inflammasome. Cytosolic DNA also triggers cGAS-STING and RIG-I-MAVS pathways. These responses lead to activation of antiviral immune responses such as INF-I and III response and production of other cytokines that result in amplifying the innate response and activation of adaptive immunity leading to viral clearance and tissue repair. [2, 3] Patients with severe COVID-19 disease manifest immune system dysregulation, which is believed to be triggered by a particular mode of programmed cell death called pyroptosis. This form of cell death induces several proinflammatory cytokines and chemokines like IL-1β, IL-2, IL-6, TNF-α, and MCP1, and lymphopenia with attrition of both CD4+ and CD8+ T cells and natural killer T cells. [3] [4] [5] IL-6 and IL-1β production promote neutrophil and cytotoxic T cell recruitment to the affected tissues, both of which contribute to tissue damage resulting in acute lung injury (ALI) through production of oxygen free radicals and inflammatory mediators like leukotrienes. [2] Indeed, elevated blood IL-6 levels have been shown to correlate with COVID-19 disease severity and SARS-CoV-2 RNA blood levels in COVID-19 patients and is also associated with worse prognosis. [6] It is hypothesized that the elevation of cytokines in COVID-19 diseases is similar to other cytokine release syndromes (CRS) observed with diseases like hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS) and chimeric antigen J o u r n a l P r e -p r o o f receptor T cell therapy (CAR-T) and that this cytokine storm is responsible for multi-organ damage observed in patients with severe COVID-19. [2] A number of immunomodulatory therapies targeting these cytokines have recently garnered interest and have been tested in COVID-19. [7] [8] [9] [10] [11] [12] [13] [14] [15] Among these, IL-6 receptor blockade with the humanized monoclonal antibody, tocilizumab is used routinely as a disease modifying agent in the treatment of rheumatoid arthritis, [16] and has been shown to be effective in the treatment of CRS associated with CAR-T therapy. [17] These observations formed the basis for targeting IL-6 as a therapeutic approach for severe COVID-19 disease. [18, 19] Several studies addressing the role of tocilizumab were subsequently published with variable results. Two recent systematic reviews [20, 21] pooled crude unadjusted data from cohort studies and concluded that tocilizumab is associated with better outcomes in COVID-19. However, their conclusions are flawed by confounding effect inherent to crude data from observational data.

Moreover, the 2 reviews have not addressed the adverse events and have not evaluated the certainty of cumulative evidence. Therefore, we sought to perform a living systematic review of randomized trials and observational studies addressing the efficacy and safety of tocilizumab in the treatment of COVID-19 patients.

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for reporting systematic review. [22] . Our review is a living systematic review. A living systematic review is a cumulative synthesis that is updated regularly as new evidence becomes available. [23] 

We included in separate analyses 1) RCTs or 2) cohort or case-control studies (at low or moderate risk of bias) reporting on the adjusted effect estimates (derived for example from conventional regression models or propensity score matching or analysis) of the association between tocilizumab use in COVID-19 patients and one of the following a-priori outcomes: (1) in-hospital mortality, (2) need for mechanical ventilation, (3) need for ICU admission, (4) J o u r n a l P r e -p r o o f composite outcomes if reported, (5) adverse events (data from RCTs only) and (6) and Scopus. Search strategy is available in the appendix (Supplement). We also searched for unpublished manuscripts using the medRxiv services and Researchsquare.com, Google and the references of eligible studies and review articles.

Eight reviewers in groups of two independently identified eligible studies (IT, HT, MA, MA, MD, YA, TK, ZAK) and extracted the data into a pre-specified data collection form in duplicate.

Any discrepancies were resolved by 2 senior reviewers (IT, TK).

In this living systematic review, 2 independent investigators (IT and ZK) receive an updated literature search file every 3 months and continuously include relevant newly published or unpublished studies as per above inclusion criteria. The relevant meta-analyses will be continuously updated, and if new evidence is available (judged by the author group in coordination with the Journal Editor in Chief), the results will be submitted for publication at regular intervals.

Five reviewers (IT, HT, MA, TK, ZK) independently and in duplicate assessed the risk of bias for each study using the (RoB 2) of the Cochrane risk-of-bias tool for randomized trials and the ROBINS-I ("Risk Of Bias In Non-randomized Studies of Interventions") for observational studies. [24] We also assessed all included cohort studies for risk of survivor bias (or immortal time bias). We considered the following analytical approaches as acceptable tools to account for J o u r n a l P r e -p r o o f survivor bias [25] [26] [27] : (1) tocilizumab use as a time-dependent variable in the regression analysis,

(2) landmark analysis, (3) structural nested accelerated failure time model, and (4) marginal structure models. Reviewers judged each criterion for risk of bias and resolved any disagreements with a senior reviewer (IT). Finally, two reviewers (HT, IT) assessed the certainty of evidence for each of our outcomes using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. [28] 

We evaluated between-studies heterogeneity using the I 2 statistic. [29] We pooled crude data from RCTs using the Mantel-Haenszel methods using fixed effect model. [30] Due to substantial heterogeneity in cohort studies, we pooled the adjusted effect estimates of the included studies using the DerSimonian-Laird random-effects model and constructed corresponding forest plots. [31] Prior to pooling, the ORs were converted to RRs using the method by Zhang and Yu. [32] For the main analyses, we included only the studies at low or moderate risk of bias.

We conducted a priori determined subgroup analyses to assess the impact of COVID-19 disease severity on response to tocilizumab therapy. We also conducted meta-regression using a-priori chosen study level baseline characteristics of patients' populations to explore causes of heterogeneity of treatment effects across studies. These variables included: characteristics of study population (age, sex, comorbidities), dosing regimen and number of tocilizumab doses, adjustment for survivor bias, ferritin, IL-6, CRP and LDH levels. Other considered variables were not included because of missing data. Finally, we constructed contour-enhanced funnel plots and performed an Egger precision-weighted linear regression test as a statistical test of funnel plot asymmetry and publication bias. [33] All analyses of cohort studies were conducted using Stata version 16 statistical software (StataCorp, College Station, Texas) and those of RCTs using Review Manager, Version 5.4, The Cochrane Collaboration.

Of 1156 citations, 24 studies (5 RCTs and 19 cohorts) (Table S1 and S2) To date, 5 RCTs (Table S1 ) have been completed but only 4 have been published [47, 55, 57, 58] . Preliminary data from another RCT (EMPACTA), [59] was identified on Google news as a press release and cross identified on (clinicaltrials.gov) to identify its objectives and details (NCT04372186) . Figure 1 shows the result of our search strategy (PRISMA flow diagram). Table S1 and S2 illustrate the general characteristics of the included studies. All studies reported on patients hospitalized with COVID-19 with varying degrees of disease severity.

Four RCTs were at low risk of bias as per ROB.2 scale (Figure 2 A) . We could not assess the risk of bias in the EMPACTA trial although it was a double-blind placebo-controlled trial. The quality of the observational studies was assessed using ROBINS-I tool ( Figure S1 ). Among included cohort studies, survivor bias was addressed in the analysis in 4 studies only [36, 38, 39, 56] (Table S2) . 

Data from 18 out of the 19 identified cohorts were used for this analysis. The study by Garcia et al [61] did not report on mortality as an individual endpoint and therefore was not included in the quantitative analysis. Among 18 cohorts at moderate risk of bias with 9850 patients, the pooled adjusted RR for mortality was 0.58 (95% CI 0.51-0.66, I 2 = 2.5%) ( Figure S2 ). This association J o u r n a l P r e -p r o o f was observed in across all stages of disease severity ( Figure 4 ). Multivariate meta-regression analyses of variables listed in methods section did not identify any study level variable associated with RR of mortality. Contour-enhanced funnel plot and Egger's test for small-study effects (P = 0.120) did not show evidence of publication bias ( Figure S3 ). Only 3 studies reported on other outcomes ( Figure S4 and S5).

All included cohort studies were at moderate risk of bias ( Figure S1 ). Survivor bias was addressed in the analysis in 4 studies [36, 38, 39, 56] only (Table S2 ). To study the potential effect of survivor bias on the observed results, we performed a post-hoc analysis where we assumed that cohort studies that did not adjust for this bias as per above approaches reported over-estimated effect estimates. Based on data from a study in COVID-19 [62] and another influenza study [63] , relative risk for mortality increased by 40-60% when treatment (such as steroids or oseltamivir) was considered as a time-dependent variable in Cox regression analysis [62] . We, therefore, multiplied the RR or HR of studies that did not adjust for survivor bias and their corresponding 95% CI by 1.6 and pooled the new adjusted effect estimates. The corrected pooled adjusted RR for mortality from the 18 cohorts was 0.77 (95% CI 0.63-0.95, I 2 =41%) ( Figure S6 ).

To facilitate interpretation and grading of the results, we calculated the absolute effect for mortality and other outcomes for both RCTs and cohort studies. Data from RCTs, at low risk of bias, showed that, in hospitalized COVID-19 patients, tocilizumab reduces the risk of mechanical ventilation with a corresponding number needed to treat 17 (95% CI 9-100). Because of the imprecision of the NNT 95% CI, this evidence was downgraded to moderate certainty evidence. Although RCTs did not show that tocilizumab has an effect on mortality, the pooled RR of 1.09 (95% CI 0.80-1.49) was imprecise with a wide 95% CI suggesting that more studies may be needed for a definitive answer. In the 5 identified RCTs, the risk of mortality in the control group was 57/553=10.3%. The sample size required for an RCT to detect an RR of 0.73 for mortality with tocilizumab (with 80% power and alpha 0.05) is 4506 patients (2253 in each arm). The total number of patients in the 5 RCTs is 772 patients in the tocilizumab group and 553 patients in the control group.

For the cohort studies, we used the baseline risk for mortality (27.3%) from the International Severe Acute Respiratory and Emerging Infection COVID-19 database. [64] The absolute risk difference in mortality was -11.5% (95% CI -13.4 % to -9.3%) with a number needed to treat to prevent one death of 9 (95% CI 7-11). The overall quality of evidence (classified as low in observational studies) remained low given the moderate risk of study bias, low risk of publication bias, direct evidence, low inconsistency, and precise estimate.

In this living systematic review and meta-analysis that included 5 RCTs and 18 cohorts as of October 2020, cumulative moderate certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. While RCTs showed that tocilizumab did not reduce short-term mortality, low certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. 

Although IL-6 inhibition dampens the host immune response and may theoretically increase the risk of infections, we did not observe a higher risk of infections or adverse events with tocilizumab use in the RCTs. Moreover, many of the cohort studies included in our review J o u r n a l P r e -p r o o f assessed patients receiving tocilizumab in the ICU; of whom many where on mechanical ventilation. The high absolute incidence of secondary bacterial infections in the ICU [70] [71] [72] that was also observed in the cohort studies is probably related to critical illness and ICU admission as opposed to the use of tocilizumab. Tocilizumab use in CRS following CAR-T therapy was not associated with increased infections. [73] Mechanisms IL-6 has pleotropic effects and plays important roles in host defense against invading organisms and tissue repair in acute environmental conditions like trauma and burns. [74, 75] It is produced by immune cells and several other types of cells in response to TLR activation and in response to other proinflammatory cytokines such as TNF α and IL-1β, and its production is also upregulated by coagulation factors like factor VIIa and thrombin. [74] IL-6 plays a pivotal role in acute phase reaction and rapidly induces acute phase proteins including CRP, antitrypsin, serum amyloid protein A (SAA), fibrinogen, ferritin, hepcidine and others. [74, 75] Some of these proteins are involved in host defense; CRP works as an opsonin through its binding to bacterial phosporylcholine and activates complement pathway while antitrypsin inactivates proteases released by pathogens and damaged cells, and hepcidine possesses antimicrobial activities. [74] Moreover, IL-6 induces B Cell differentiation and antibody production, and induces cytotoxic T cell differentiation from CD8 T cells. It also promotes the induction of C3 complement and C5a receptor. [74, 75] IL-6 also increases the production of intercellular adhesion molecule-1 (ICAM-1), MCP-1 and IL-8, which play role in migration of inflammatory cells to sites of inflammation and tissue damage. [74] All of these effects are very important in host defense against invading pathogens. However, persistent and dysregulated production of IL-6 may have detrimental effects and IL-6 has been identified as an important mediator in different autoimmune and chronic inflammatory diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. [74, 75] Additionally, the production of IL-6 has been shown to be increased significantly in conditions associated CRS and cytokine storm like CAR-T therapy, MAS, HLH syndromes and viral infections associated with cytokine storm. [74, 75] IL-6 plays a crucial role in the pathogenesis of CRS associated with these conditions. IL-6 increases vascular permeability leading to interstitial edema, increased tissue pressure and damage through activation of complement system, induction of vascular J o u r n a l P r e -p r o o f endothelial growth factor (VEGF) and histamine release from mast cells. It also activates coagulation system through increased production of factor VIIa, thrombin and tissue factor, and induction of megakaryocyte maturation and platelet production. These procoagulation effects can lead to DIC. Furthermore, IL-6 has direct myocardial depressing effects. [74] Therefore, these effects of IL-6 could explain the manifestations of COVID-19 associated cytokine storm which include hypoxemia, hypotension, intravascular thrombosis, myocardial dysfunction and multiorgan failure. Several lines of evidence support this contention. For example, IL-6 injection in patients with breast and lung cancer have been shown to produce fever and influenza like symptoms. [76] It has also been shown that injecting metastatic renal cancer patients with IL-6 induces coagulation activation as evidenced by increased thrombin-antithrombin III complexes and increased plasma levels of prothrombin activation fragment. 

Although IL-6 level determination is not performed routinely in most hospital, acute phase proteins can serve as surrogate markers for elevated IL-6 in COVID-19 disease, especially, CRP and ferritin as their assays are widely available. Therefore, CRP and ferritin can be used as markers of elevated IL-6 to help in selecting candidate COVID-19 patients for tocilizumab therapy. Indeed, in a multicenter study that included 1,229 COVID-19 patients from Spain, it was found that tocilizumab reduced risk of mortality only in patients with baseline CRP levels J o u r n a l P r e -p r o o f above 150 mg/L (aHR 0.34, 95% CI 0.16-0.72, p=0.005).

[38] This indicates that patients with low CRP likely had low IL-6 levels and hence, did not respond favorably to tocilizumab.

Tocilizumab was also shown to significantly reduce CRP and ferritin among COVID-19 disease patients. [79] D-dimer which is another biomarker that is usually elevated in patients with COVID-19 disease and that may indicate presence of intravascular thrombosis was also found to predict outcomes to tocilizumab. [79] These studies indicate that not all COVID-19 patients respond equally to tocilizumab, which is likely reflecting the heterogeneous nature of the disease and the possibility that it encompasses different sub-phenotypes. Postmortem studies lend support to this hypothesis as autopsy series from Italy and USA showed that some COVID-19 patients exhibit extensive pulmonary inflammation and alveolar damage while others manifest severe vascular endothelial damage and intravascular thrombosis. [80, 81] In addition, in the RECOVERY trial, only patients with underlying hypoxemia had improved survival with dexamethasone therapy, reflecting possible presence of different sub-phenotypes with differential response to immunomodulatory therapies [do we have the reference]. Similar phenomenon has been observed in patients with sepsis. Reanalysis of the phase-III trial of anti-IL-1β antibody (anakinra) therapy in sepsis patients revealed that only patients who had features of MAS (5.6% of patients) had markedly reduced mortality in response to anakinra. [82] Further studies are needed to identify COVID-19 patients who would respond favorably to immunomodulatory therapies.

Our meta-analysis has several strengths; we included published and unpublished randomized trials, employed rigorous methodologies and excluded unadjusted crude effect estimates from cohort studies. Our inclusion of real-world data from good quality observational studies and randomized trials allowed us to explore sources of heterogeneity and compare the results of the RCTs with those of cohort studies. Although observational studies are prone to different biases; including confounding by indication, survivor bias and residual confounding, empirical studies have shown that pooled estimates from meta-analyses of observational studies yield similar estimates to those pooled from RCTs. [66, 67] [68, 69] .

Conclusion Cumulative moderate certainty evidence shows that tocilizumab reduces the risk of mechanical ventilation in hospitalized COVID-19 patients. While RCTs showed that tocilizumab did not reduce short-term mortality, low certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. We did not observe a higher risk of infections or adverse events with tocilizumab use. This review will continuously evaluate the role of tocilizumab in COVID-19 treatment. 

Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review

The many faces of the anti-COVID immune response

The trinity of COVID-19: immunity, inflammation and intervention

Clinical and immunological features of severe and moderate coronavirus disease 2019

Dysregulation of immune response in patients with Coronavirus

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet Rheumatology

GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? The Lancet Rheumatology

Anakinra in COVID-19: important considerations for clinical trials. The Lancet Rheumatology

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. The Lancet Rheumatology

Preventing COVID-19-induced pneumonia with anticytokine therapy. The Lancet Rheumatology

Can tocilizumab calm the cytokine storm of COVID-19? The Lancet Rheumatology

The immunology of COVID-19: is immune modulation an option for treatment? The Lancet Rheumatology

Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies

Chimeric antigen receptor T cells for sustained remissions in leukemia

Effective treatment of severe COVID-19 patients with tocilizumab

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv

Efficacy of tocilizumab in COVID-19: A systematic review and metaanalysis

Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies

The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration

Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias

Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome

Methods for time-varying exposure related problems in pharmacoepidemiology: An overview

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Measuring inconsistency in meta-analyses

Analysing data and undertaking metaanalyses, in Cochrane Handbook for Systematic Reviews of Interventions version 6

Meta-analysis in clinical trials

What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms

A study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia (COVACTA)

Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology

Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial

Efficacy of tocilizumab in patients hospitalized with COVID-19

Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients -An observational study. medRxiv

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Systemic corticosteroids show no benefit in severe and critical COVID-19 patients in Wuhan, China: A retrospective cohort study

Survival biases lead to flawed conclusions in observational treatment studies of influenza patients

ISARIC COVID-19 Clinical Data Report: 8

The conundrum of interleukin-6 blockade in COVID-19. The Lancet Rheumatology

Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials

Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles

Randomized, controlled trials, observational studies, and the hierarchy of research designs

A comparison of observational studies and randomized, controlled trials

Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis

Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality

Intensive care unit-acquired blood stream infections: a 5-year retrospective analysis of a single tertiary care hospital in Korea. Infection

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?, in Blood

Immunotherapeutic implications of IL-6 blockade for cytokine storm

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study

Interleukin-6 stimulates coagulation, not fibrinolysis, in humans

The acute phase protein response in patients receiving subcutaneous IL-6

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases

Megakaryocytes and platelet-fibrin thrombi characterize multiorgan thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine

Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial